IQInvest research note
25 AUG 2026 · 17:04 ET
REGN
Regeneron Pharmaceuticals, Inc.
$834.65
$6.15 (+0.74%)up 0.74%
25 August 2026 · delayed 15+ min
C-
Cut-offs are the grader's own: 97+ for an A+, below 60 is an F.
Regeneron Pharmaceuticals, Inc. earns a C- on excellent profit margins (>20%) and strong current ratio (>2.0) but high debt-to-equity ratio (>2.0) and negative earnings growth. Reasonable investment with moderate upside potential.
Adjusted for Moderate investors, Medium-term investors 5.1% suggested allocation Change these
IQ-REGN-20260825engine v1 · 7-category weighted scorecard